Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Posts Surge in Q4 Revenue, Narrowed Loss

NEW YORK, Feb. 12 - Epoch Biosciences on Tuesday reported a surge in total revenues for the fourth quarter 2001 and a narrowed loss as strong sales outpaced a slight jump in operating costs.

 

For the period ended Dec. 31, the genomics tool company reported total revenue of $2.2 million compared with $945,000 one year ago, driven by a jump in license fees and royalties to $722,000 from $30,000 year over year.

Product sales also helped nudge the top line as the company sold $946,000 of its Eclipse PCR tools and its DNAnchor microarrays compared with $665,000 the firm earned in sales in the same period one year ago.


Revenue from contract research also grew in the quarter, to $585,000 from $250,000 one year ago, thanks in part to a research collaboration and part of a SBIR grant awarded to the company in 2001.

 

Leading a modest increase in total operating expenses, R&D spending inched up to $1.4 million from $1.1 million in the year-ago period, though net loss still managed to fall to $934,000, or $.04 per share, from $1.4 million, or $.05 per share, recorded in the same period last year.

 

Shares in the Bothell, Wash.-based were off $.01, or about half a percent, to $1.94 in mid-morning Nasdaq trade.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.